Your browser doesn't support javascript.
loading
The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Zhang, Xiaowei; Wu, Yuchen; Sun, Xuefei; Cui, Qu; Bai, Xueyan; Dong, Gehong; Gao, Zifen; Wang, Yaming; Gao, Chunji; Sun, Shengjun; Ji, Nan; Liu, Yuanbo.
Afiliación
  • Zhang X; Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Nan Si Huan Xi Lu 119, Fengtai District, Beijing, 100070, China.
  • Wu Y; Department of Hematology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Sun X; Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Nan Si Huan Xi Lu 119, Fengtai District, Beijing, 100070, China.
  • Cui Q; Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Nan Si Huan Xi Lu 119, Fengtai District, Beijing, 100070, China.
  • Bai X; Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Nan Si Huan Xi Lu 119, Fengtai District, Beijing, 100070, China.
  • Dong G; Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Nan Si Huan Xi Lu 119, Fengtai District, Beijing, 100070, China.
  • Gao Z; Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Wang Y; Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Gao C; Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Sun S; Department of Hematology, Chinese PLA General Hospital, Beijing, China.
  • Ji N; Neuroimaging Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Liu Y; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
BMC Cancer ; 22(1): 190, 2022 Feb 20.
Article en En | MEDLINE | ID: mdl-35184749
ABSTRACT

BACKGROUND:

Primary central nervous system lymphoma (PCNSL) is a specific subtype of non-Hodgkin lymphoma that is highly invasive and confined to the central nervous system (CNS). The vast majority of PCNSLs are diffuse large B-cell lymphomas (DLBCLs). PCNSL is a highly heterogeneous disease, and its pathogenesis has not yet been fully elucidated. Further studies are needed to guide individualized therapy and improve the prognosis.

METHODS:

In this study, we detected 1) the expression of p-AKT, p-mTOR, p-S6 and p-4E-BP1 by immunohistochemistry (IHC) and Western blotting, 2) the mRNA expression by real-time qPCR and 3) the deletion of PTEN gene by immunofluorescence in situ hybridization (FISH) in order to investigate the activation status of the PI3K/AKT/mTOR signaling pathway in PCNSL. Samples of reactive hyperplasia lymphnods were used as the control group. The correlations between the clinical characteristics and prognosis of PCNSL patients and the expression of p-AKT, p-mTOR, p-S6 and p-4E-BP1 and the deletion of PTEN were assessed.

RESULTS:

The IHC results showed that the positive expression rates of p-AKT, p-mTOR, p-S6 and p-4E-BP1 in PCNSL were significantly higher in the PCNSL group than in the control group (P < 0.05). The relative mRNA expression level of MTOR in PCNSL samples was significantly increased (P = 0.013). Correlation analysis revealed that the expression of p-mTOR was correlated with that of p-AKT, p-S6, p-4E-BP1. PTEN deletion was found in 18.9% of PCNSL samples and was correlated with the expression of p-AKT (P = 0.031). Correlation analysis revealed that the PCNSL relapse rate in the p-mTOR-positive group was 64.5%, significantly higher than that in the negative group (P = 0.001). Kaplan-Meier survival analysis showed inferior progression-free survival (PFS) in the p-mTOR- and p-S6-positive groups (P = 0.002 and 0.009, respectively), and PTEN deletion tended to be related to shorter overall survival (OS) (P = 0.072). Cox regression analysis revealed p-mTOR expression as an independent prognostic factor for a shorter PFS (hazard ratio (HR) =7.849, P = 0.046).

CONCLUSIONS:

Our results suggest that the PI3K/AKT/mTOR signaling pathway is aberrantly activated in PCNSL and associated with a poor prognosis, which might indicate new therapeutic targets and prognostic factors.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Neoplasias del Sistema Nervioso Central / Fosfatidilinositol 3-Quinasas / Proteínas Proto-Oncogénicas c-akt / Serina-Treonina Quinasas TOR Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Neoplasias del Sistema Nervioso Central / Fosfatidilinositol 3-Quinasas / Proteínas Proto-Oncogénicas c-akt / Serina-Treonina Quinasas TOR Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: China